Eric Topol

Because that doesn't even exist right now.

I think you're pointing out one of the most important things going on in medicine today is how we didn't anticipate that live cell therapy of engineered cells, and ideally off the shelf or in vivo, not just having to take them out and work on them outside the body, is a revolution ongoing.

And it's not just in cancer.

It's in autoimmune diseases and many others.

So it's part of the virtual cell need.

We need this.

One of the things that's a misnomer I want you both to comment on, we keep talking about single-cell.

There's a paper, Spatial Multiomics this week, five different single-cell scales all integrated, it's great, but we don't get to single-cell.

We're basically looking at 50 cells, 100 cells.

We're not doing single cell because we're not going deep enough.

Is that just a matter of time when we actually are doing it?

Of course, the more we do get down to the single or a few cells, the more insights we're going to get.

Would you comment about that?

Because, you know, we have all this literature on single cell comes out every day, but we're not really there yet.

Right.

Yeah, Steve, I mean, you kind of comment on that and the amazing progress that we have made with space and time, spatial temporal resolution, spatial omics over these years, but that we still could go deeper in terms of getting to individual cells, right?

I'm just trying to identify some of the multitude of challenges in this extraordinarily bold initiative because there are no shortage and that's what's good about it.

It's given people lots of work to do to overcome, override some of these challenges.

Before we wrap up, besides the fact that you point out that all the work has to be done and be validated in real experiments, not just live in a virtual AI world, but you also comment about the safety and ethics of this work and assuming you're going to gradually get there and be successful.

So could either or both of you comment about that?